9月15日，哈佛医学院研究团队在《Nature Communications》上发表题为“Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment”的研究论文，描述了一种广泛适用的非遗传方法，该方法同时解决了CAR T作为实体瘤疗法的多重挑战。该方法通过将CAR-T细胞暴露于已暴露于...
Vile 研究组在Science Translational Medicine上发表题为Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice的文章,改进了上述CAR T疗法。 首先,作者之前的工作采用小鼠黑色素瘤模型,在转输CAR T细胞之前瘤内注射溶瘤病毒(VSV-mIFN)。作者发现注射溶瘤...
2022年8月25日,美国休斯顿卫理公会癌症中心/威尔康奈尔医学院鲁勇团队在Cancer Cell期刊发表了题为"Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance"的研究论文。 在这项研究中,该团队报告了经粘液瘤病毒(MYXV)感染的CAR-T和TCR- ...
The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and...
2024年11月20日,浙江大学顾臻、王金强、车金鑫等在Advanced Materials上发表题为“An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity”的研究。该研究开发了一种靶向HPK1的口服蛋白水解靶向嵌合体(PROTAC),能够有效、特异性地降解HPK1,增强免疫治疗效果。PROTAC和CAR-T细胞的协同应用有效...
2024年8月12日,美国耶鲁大学医学院陈斯迪团队在期刊《Cellular & Molecular Immunology》上发表了题为“T CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors”的研究论文。在这篇综述中,团队探讨了CAR-T和CAR-NK细胞...
OV联用CAR-T已成为当下攻克实体瘤治疗难题的主流研究方向之一。不过,也有一些研究突破了联用治疗的传统范式,利用CAR-T细胞系统性递送溶瘤病毒,获得了更好的治疗效果。 2022年8月25日,美国休斯顿卫理公会癌症中心/威尔康奈尔医学院鲁勇团队在Cancer Cell期刊发表了题为"Induction of tumor cell autosis by myxoma vi...
2023年10月,《Nature reviews clinical oncology》发布了宾夕法尼亚大学Steven M. Albelda教授撰写的题为“CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn”的综述文章,系统性地阐述了细胞治疗当前面临的困境——即CAR-T细胞在大多数实体肿瘤中的疗效仍然难以确定。Albelda教...
CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019). CAS PubMed PubMed Central Google Scholar Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current ...
The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and...